Validation of ERX-208 in Ovarian Cancer

Seattle, WA - September 23, 2024: Dr. Surya Viswanadhapalli and Etira founder Dr Ratna Vadlamudi presented a poster titled “The therapeutic potential of ERX-208, a potent inducer of ER stress, in the treatment of ovarian cancer” at the 15th Biennial Ovarian Cancer Research Symposium. The data establishes that ER stress in ovarian cancer (OCa) is targetable and the clinical utility of ERX-208.

ERX-315-001 SITE INITIATION VISIT @TKCC

Sydney, Australia – September 4, 2024:  The Etira team, led by Founder Dr. Ganesh Raj, and the clinical Contract Research Organization Novotech successfully performed the site initiation visit at the Kinghorn Cancer Center (TKCC) in Sydney…